Our Work
Latham & Watkins Advises Genascence in Series A Financing
May 12, 2022
A California-based team advises the clinical-stage biotechnology company in the funding round.
Genascence Corporation (Genascence), a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with gene therapy, has announced it has completed the first closing in a Series A financing led by Pacira BioSciences, Inc., totaling US$10.5 million. Additional investors included Polymerase Capital, DeepWork Capital, and University of Florida Research Foundation.
Latham & Watkins Advises Genascence in the funding round with a deal team led by Bay Area partners Ben Potter and Judith Hasko, with Century City associate Simon Moshkovich.